Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sevoflurane + propofol is a combination of two anesthetic agents used together to induce and maintain general anesthesia. Sevoflurane is an inhalational volatile anesthetic, while propofol is an intravenous sedative-hypnotic agent. When administered in combination, they act additively to produce loss of consciousness and immobility for surgical procedures. This combination can provide stable respiration and circulation during anesthesia, rapid recovery of consciousness, reduced cough reflex during certain surgeries (such as nonintubated video-assisted thoracic surgery), and a low incidence of adverse reactions[2][3][4]. Both drugs primarily enhance inhibitory neurotransmission via the gamma-aminobutyric acid type A (GABA-A) receptor in the central nervous system; sevoflurane also modulates other ion channels including glycine receptors, glutamate receptors, calcium channels, potassium channels, and sodium/calcium exchange currents[2][5]. The use of this combination may be particularly suitable for patients requiring stable hemodynamics or those at risk for cardiovascular complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sevoflurane + propofol.